Wednesday, October 14, 2026

Less Than Two Hours Before The Market Open, Verisk Analytics Is Down By 5%

ViaNews Editorial Team

January 16, 2024

Less Than Two Hours Before The Market Open, Verisk Analytics Is Down By 5%

(VIANEWS) - The NASDAQ opens in less than two hours and Verisk Analytics's pre-market value is already 5.47% down.

Verisk Analytics's last close was $236.77, 5.01% under its 52-week high of $249.26.

The last session, NASDAQ finished with Verisk Analytics (VRSK) rising 1.09% to $236.77. NASDAQ rose 0.02% to $14,972.76, following the last session's upward trend on what was a somewhat positive trend trading session.

About Verisk Analytics

Verisk Analytics, Inc. provides data analytics solutions to the insurance markets in the United States and internationally. The company provides predictive analytics and decision support solutions to customers in rating, underwriting, claims, catastrophe and weather risk, global risk analytics, and various other fields. It focuses on the prediction of loss, selection and pricing of risk, and compliance with their reporting requirements for property and casualty insurance customers, as well as develops machine learned and artificially intelligent models to forecast scenarios and produce standard and customized analytics that help its customers to manage their businesses, including detecting fraud before and after a loss event, and quantifying losses. The company was founded in 1971 and is headquartered in Jersey City, New Jersey.

Earnings Per Share

As for profitability, Verisk Analytics has a trailing twelve months EPS of $5.32.

PE Ratio

Verisk Analytics has a trailing twelve months price to earnings ratio of 44.51. Meaning, the purchaser of the share is investing $44.51 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 66.78%.

More news about Verisk Analytics (VRSK).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com